Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 5 5 W O ELECTROLYTES.
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 5% with electrolytes in dextrose 25% provides amino acids for protein synthesis, dextrose for caloric supply, and electrolytes for maintenance of acid-base balance and cellular function. Calcium is included for bone health and neuromuscular function.
TRAVASOL 5.5% W/O ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and nitrogen balance in patients unable to tolerate enteral nutrition. It serves as a substrate for gluconeogenesis and other metabolic processes.
Intravenous; initial adult dose 1.0 g/kg/day of amino acids, up to 1.5 g/kg/day; dextrose rate 5 mg/kg/min initially, titrate to 7 mg/kg/min; daily dose adjusted based on metabolic requirements, electrolytes as per serum levels.
Intravenous infusion, 500 mL to 2000 mL per day as a component of total parenteral nutrition (TPN), providing 5.5% amino acids. Rate should be individualized based on metabolic requirements and tolerance.
None Documented
None Documented
Not applicable as a single entity; component amino acids have half-lives ranging from minutes (e.g., alanine) to hours (e.g., branched-chain amino acids); dextrose half-life ~1.5-2 hours in normal glucose metabolism; clinical context: continuous infusion maintains steady state.
Not applicable as a fixed drug; the clearance of infused amino acids follows saturable kinetics with a functional half-life of approximately 30-60 minutes for free amino acids in plasma, reflecting rapid uptake and metabolism. Clinical context: continuous infusion maintains steady-state levels.
Renal: amino acids and dextrose metabolites excreted primarily as urea, CO2, and water; electrolytes excreted renally with fractional excretion varying by individual needs; no significant biliary or fecal elimination.
Primarily renal excretion of amino acids and metabolites; approximately 70-80% of infused amino acids are converted to urea and excreted in urine, with the remainder undergoing metabolism or incorporation into body proteins. Biliary/fecal excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution